About Immunocore
Immunocore is a company based in Abingdon (United Kingdom) founded in 2008 by Nicholas John Cross and George Kelly Martin. Immunocore has raised $601.28 million across 9 funding rounds from investors including Lilly, WuXi AppTec and BlackRock. The company has 493 employees as of December 31, 2024. Immunocore operates in a competitive market with competitors including Senti Biosciences, Caribou Biosciences, Autolus, Cargo Therapeutics and Achilles Therapeutics, among others.
- Headquarter Abingdon, United Kingdom
- Employees 493 as on 31 Dec, 2024
- Founders Nicholas John Cross, George Kelly Martin
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh
-
Annual Revenue
$310.33 M (USD)23.94as on Dec 31, 2024
-
Net Profit
-$51.11 M (USD)7.91as on Dec 31, 2024
-
EBITDA
-$66.28 M (USD)-18.87as on Dec 31, 2024
-
Total Equity Funding
$601.28 M (USD)
in 9 rounds
-
Latest Funding Round
$140 M (USD), Post-IPO
Jul 18, 2022
-
Investors
Lilly
& 12 more
-
Employee Count
493
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Immunocore
Immunocore is a publicly listed company on the NASDAQ with ticker symbol IMCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Immunocore
Unlock access to complete
Unlock access to complete
Funding Insights of Immunocore
Immunocore has successfully raised a total of $601.28M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $140 million completed in July 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Immunocore
Immunocore has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, WuXi AppTec and BlackRock.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Private equity fund focused on global markets
|
Locked | Locked | Locked | |
|
Companies developing T1D products are funded through venture philanthropy.
|
Locked | Locked | Locked |
Investor details for Immunocore
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Immunocore
Investment portfolio details for Immunocore
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Immunocore
Detailed financials for Immunocore
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Immunocore Comparisons
Peer comparison for Immunocore
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Immunocore
Immunocore operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Caribou Biosciences, Autolus, Cargo Therapeutics and Achilles Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Cell-based therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
T-cell therapies targeting tumor neo-antigens for cancer are developed.
|
Detailed competitors of Immunocore
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Immunocore
Complete news archive for Immunocore
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Immunocore
Immunocore was founded in 2008.
Immunocore is headquartered in Abingdon, United Kingdom. It is registered at Abingdon, Oxfordshire, United Kingdom.
Immunocore is a funded company, having raised a total of $601.28M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Immunocore is 493.
Annual revenue of Immunocore is $310.33M as on Dec 31, 2024.
Immunocore was founded in 2008 in Abingdon, United Kingdom, within the biotechnology sector focused on oncology. Proprietary ImmTAC molecules are developed to mobilize the immune system against cancer cells by targeting peptide-HLA complexes and triggering T-cell responses via anti-CD3 fragments. Operations center on advancing bi-specific immunotherapeutics, with the lead candidate IMCgp100 directed toward uveal melanoma treatment.
Immunocore's top competitors include Achilles Therapeutics, Autolus and Senti Biosciences.
Yes, Immunocore is publicly traded on NASDAQ under the ticker symbol IMCR.
Immunocore has 13 investors. Key investors include Lilly, WuXi AppTec, BlackRock, General Atlantic, and Gates Foundation.
The ticker symbol of Immunocore is IMCR on NASDAQ.
The valuation of Immunocore is $777.28M as of Jul 2015.